Editor David Bluemke, MD, PhD, says the journal’s rising impact factor is “representative of the fundamental importance of imaging throughout our hospitals and clinics.”

The FDA has cleared a focused-ultrasound developer to compare the safety and efficacy of acoustic energy for treating prostate cancer against the more conservative approach of active surveillance.

The FDA is warning patients and referrers about an imaging business near the nation’s capital that has fumbled away its mammography accreditation.

One of the largest private health insurers in the U.S. has gone from considering hybrid PET/CT for cardiac indications “experimental/investigational” to displaying willingness to pay for the modality. 

A convolutional neural network has achieved 99.67% accuracy at flagging the presence of pacemakers on chest radiographs in patients referred for MRI.

Rumors have been swirling for more than a year, but a Siemens Healthineers C-suite executive has declared the company’s ultrasound business alive, well and amply resourced.

Researchers had 40 participants inhale polarized xenon gas in order to conduct 129Xe MRI exams for the study.

The FDA would approve trials on a case-by-case basis, according to an anonymous source close to the situation. 

The company thinks its new technology can help physicians spend more time with patients and less time filling out paperwork.